Introduction
============

Dopamine (DA) is a catecholamine neurotransmitter released by neurons in a number of regions of the mammalian brain, and is thought to be important in the expression of a wide variety of behaviors \[[@b1-sensors-05-00317]-[@b3-sensors-05-00317]\]. DA in the basal ganglia is involved in motor control, and a causative link has been established between loss of DA in the dorsal striatum, due to neurodegeneration, and Parkinson\'s disease in humans \[[@b4-sensors-05-00317]\]. In the prefrontal cortex, DA regulates cognitive functions \[[@b5-sensors-05-00317]\]; DA imbalance in this region can lead to attention disorders and has been implicated in the pathophysiology of schizophrenia \[[@b6-sensors-05-00317]-[@b9-sensors-05-00317]\]. Another important role for DA has been established in the expression of 'rewarding' behaviors \[[@b10-sensors-05-00317],[@b11-sensors-05-00317]\], such as eating \[[@b12-sensors-05-00317],[@b13-sensors-05-00317]\] and sexual activity \[[@b14-sensors-05-00317],[@b15-sensors-05-00317]\]. Indeed, many of the common drugs of abuse (e.g., cocaine \[[@b16-sensors-05-00317]\], amphetamine \[[@b17-sensors-05-00317]\] and 'ecstasy' \[[@b18-sensors-05-00317]\]) have specific actions on brain DA systems, and this mechanism may be involved in the addictive properties of these agents. The ability to monitor a real-time index of DA release in discrete brain areas during well defined behaviors, and in response to pharmacological challenges, would provide an important key to understanding more fully the role this molecule plays in brain function.

A growing number of methodologies are being developed, including sampling \[[@b19-sensors-05-00317],[@b20-sensors-05-00317]\], spectroscopic \[[@b21-sensors-05-00317]\] and electrochemical \[[@b16-sensors-05-00317],[@b22-sensors-05-00317],[@b23-sensors-05-00317]\], to study neurochemical phenomena in the intact brain. One such set of techniques focuses on the *in-situ* detection of substances in brain extracellular fluid (ECF), using *in-vivo* voltammetry (IVV) with implanted amperometric electrodes. A number of reviews on the principles and applications of IVV analysis of the ECF have been published, and a representative selection is cited here \[[@b24-sensors-05-00317]-[@b39-sensors-05-00317]\]. This paper reviews the application of one approach to monitoring neurochemical dynamics in brain extracellular space: the use of chronically implanted carbon paste electrodes (CPEs) that are stable enough to detect a metabolite of DA continuously over periods of months.

It should be stressed that the application of IVV involves far more than a straightforward transfer of expertise gained from the practice of voltammetry *in vitro*. In addition to being anatomically complicated and containing a wide range of electroactive substances, brain tissue presents a complex chemical environment that includes surfactants (lipids), electrodes poisons (proteins), electrocatalysts such as glutathione and ascorbate, and a tissue matrix that both restricts mass transport to the electrode surface and reacts physiologically to the presence of the probe \[[@b40-sensors-05-00317]\]. Thus, the behavior of a particular electrode and voltammetric technique *in vitro* might well be different to its behavior *in vivo*, because both modification of the electrode surface by components of the tissue \[[@b41-sensors-05-00317],[@b42-sensors-05-00317]\], and the differences in mass transport \[[@b43-sensors-05-00317]-[@b46-sensors-05-00317]\], could lead to different responses (sensitivity, selectivity, stability, etc.) in the two environments \[[@b47-sensors-05-00317]\]. Therefore, detailed characterization *in vitro* of parameters such as detection limits is of little use, and may be misleading in an application like IVV where the major issue is that of selectivity rather that sensitivity. An example of the complications involved in characterizing an IVV technique *in vivo* is that of time scale: a technique demonstrated to detect DA selectively on a fast time scale (seconds) cannot be assumed to do so on slower time scales (minutes) because changes in neurotransmitter concentrations tend to be much faster than those of their metabolites \[[@b48-sensors-05-00317]\]. Issues such as these have been addressed recently in the literature \[[@b49-sensors-05-00317],[@b50-sensors-05-00317]\].

Dopamine Biochemistry
=====================

[Figure 1](#f1-sensors-05-00317){ref-type="fig"} shows a schematic representation of intercellular chemical signaling at a synapse between a DA nerve terminal and target neuron. The precursor amino acid tyrosine is taken from the ECF into the terminal where tyrosine hydroxylase (rate-determining step) and DOPA decarboxylase transform it into the neurotransmitter DA. Although most of the newly synthesized neurotransmitter is taken up into storage vesicles, some will be inactivated before reaching the vesicles by metabolic enzymes present in the terminal, especially monoamine oxidase. When an action potential (rapid depolarization, followed by repolarization of the membrane potential; total duration about 5 ms) propagates down an axon to the nerve terminal, voltage-sensitive Na^+^ ion channels open, causing depolarization of the terminal membrane and the opening of voltage-sensitive Ca^2+^ channels, the influx of Ca^2+^, and fusion of vesicles that release their neurotransmitter content into the synapse; a few milliseconds later, the opening of voltage-sensitive K^+^ channels results in repolarization ([Figure 1](#f1-sensors-05-00317){ref-type="fig"}). This Ca^+2^-dependent exocytotic release of neurotransmitter is surprisingly fast in the mammalian brain, occurring within microseconds of the start of the action potential upswing in the terminal \[[@b51-sensors-05-00317]\].

Once in the synapse, the neurotransmitter molecules may bind to a range of different receptor proteins on either the presynaptic or postsynaptic membrane. On the presynaptic side, receptors may be linked to a "second messenger" enzyme involved in regulating the activity of the rate-determining enzyme used in the synthesis of neurotransmitter (local negative feedback control). Postsynaptically, receptors may also be linked to a second messenger system, or to ion channels for Na^+^, K^+^ or Cl^-^ that control the membrane potential of the target neuron. Inactivation of the chemical signal is achieved either by re-uptake of neurotransmitter into the terminal (and other sites, such as glial cells) through specific ion-coupled carrier uptake sites and subsequently metabolized, or may be metabolized extracellularly. The metabolites diffuse into the ECF that also contains a low concentration of neurotransmitter that overflows from the synapse ([Figure 1](#f1-sensors-05-00317){ref-type="fig"}).

One of the key elements in understanding the role of each neurotransmitter substance in neural networks is a knowledge of release rate, and Adams et al. \[[@b54-sensors-05-00317]\] suggested that amperometric electrodes implanted directly in the intact brain might be used to monitor electroactive neurotransmitters in the CNS. However, electrodes generally employed for neurochemical analysis using IVV are ∼5-300 μm in diameter and monitor an average concentration of analyte in the medium surrounding cells, the ECF, and not directly in synapses that are orders of magnitude smaller (typically 20-30 nm; see [Figure 1](#f1-sensors-05-00317){ref-type="fig"}). It is not clear at present what the relationship is between release of different neurotransmitters into the synapse and resulting ECF levels, although balance between release and re-uptake ([Figure 1](#f1-sensors-05-00317){ref-type="fig"}) is involved \[[@b55-sensors-05-00317],[@b56-sensors-05-00317]\]. It is also debatable whether neurotransmitters released into a synapse have additional extrasynaptic functions, so that the synapse might be designed to 'leak'. For example, extrasynaptic receptors have been reported for the main excitatory CNS neurotransmitter, glutamate \[[@b57-sensors-05-00317]\], as well as evidence for the diffusion of glutamate outside the synaptic cleft \[[@b58-sensors-05-00317]\]. Thus, monitoring the overflow of transmitter in the ECF is one index of release rate. Another is the concentration of metabolite in the ECF, although caution is needed in the interpretation of metabolite data because changes in synthesis rate can also affect metabolite levels, independent of release \[[@b59-sensors-05-00317]-[@b61-sensors-05-00317]\].

Carbon Paste Electrodes for *In-Vivo* Voltammetry
=================================================

Since its invention in the late 1950s \[[@b62-sensors-05-00317]\], the CPE has continued to offer a versatile substrate for electroanalysis, mainly because of the ease with which the bulk or surface of this electrode material can be modified with inorganic, organic and biological molecules \[[@b63-sensors-05-00317]-[@b67-sensors-05-00317]\]. In addition to the neurochemical studies cited below, applications of CPEs include environmental monitoring \[[@b68-sensors-05-00317],[@b69-sensors-05-00317]\], drug analysis \[[@b70-sensors-05-00317]-[@b72-sensors-05-00317]\], determination of heavy metals \[[@b73-sensors-05-00317]\] and toxins \[[@b74-sensors-05-00317]\], biomedical monitoring \[[@b66-sensors-05-00317],[@b75-sensors-05-00317]-[@b79-sensors-05-00317]\], and food analysis \[[@b80-sensors-05-00317],[@b81-sensors-05-00317]\].

For applications involving implantation into biological tissues, carbon paste, prepared by thoroughly mixing carbon powder with either Nujol \[[@b54-sensors-05-00317]\] or silicone oil \[[@b82-sensors-05-00317]\] can be easily packed into cavities created by pulling the insulation over fine metal wires, producing disk electrodes of diameters as small as 160 μm, although diameters of about 300 μm have been generally used for IVV ([Figure 3](#f3-sensors-05-00317){ref-type="fig"}). A carbon/Nujol paste electrode with CV was used in one of the first reports of voltammetry in brain tissue with the aim of studying DA \[[@b54-sensors-05-00317]\]; a single peak was observed in rat striatum, attributed mainly to the oxidation of ascorbate. Decreasing the scan rate to 10 mV/s and semidifferentiation of the current later revealed three rather broad waves on the striatal voltammogram \[[@b83-sensors-05-00317]\]. Further developments of the technique by the use of computer-controlled equipment \[[@b84-sensors-05-00317]\], silicone oil paste \[[@b82-sensors-05-00317]\], an additional reduction of the sweep rate to 5 mV/s, abandoning semidifferentiation, and subtraction of the background current recorded *in situ*, yielded CPE voltammograms consisting of three well-separated peaks in striatal tissue \[[@b85-sensors-05-00317]\] (see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}).

Peak-shaped signals are obtained by this non-differential method due to both thin-layer behavior in the compartment around the implanted electrode \[[@b43-sensors-05-00317],[@b90-sensors-05-00317],[@b91-sensors-05-00317]\] and adsorption of the analytes \[[@b41-sensors-05-00317],[@b88-sensors-05-00317]\]. Because of the lack of clear resolution between ascorbate and catechols by CPEs, a wide variety of techniques have been used to characterize the CPE signals recorded in rat striatum *in vivo*: theoretical analysis \[[@b91-sensors-05-00317]\]; electrochemical studies *in vitro* \[[@b47-sensors-05-00317],[@b82-sensors-05-00317],[@b84-sensors-05-00317]\]; microinfusion of microlitre solutions of candidate substances \[[@b84-sensors-05-00317],[@b92-sensors-05-00317]\] and metabolizing enzymes \[[@b88-sensors-05-00317],[@b93-sensors-05-00317]-[@b95-sensors-05-00317]\] beside electrodes implanted in brain tissue; lesions to striatal afferent pathways \[[@b59-sensors-05-00317],[@b93-sensors-05-00317],[@b96-sensors-05-00317]\]; pharmacological perturbations using drugs with well-characterized actions \[[@b59-sensors-05-00317],[@b87-sensors-05-00317],[@b92-sensors-05-00317],[@b94-sensors-05-00317]\]; and comparison with other *in-vivo* techniques, such as microdialysis \[[@b88-sensors-05-00317],[@b97-sensors-05-00317]\].

These experiments have been reviewed \[[@b40-sensors-05-00317]\] and indicate that peak 1 (see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) is due mainly to ascorbate; moreover changes in the height of peak 1 result from variations in the extracellular concentration of ascorbate, provided there is no significant shift in the relative potentials of peaks 1 and 2. When such potential shifts occur they are not due to electrocatalysis but to the algebraic combination of the ascorbate peak (at the normal potential of peak 1) and the catechol peak some 60 mV higher, and difference voltammograms can be used to analyze the changes in terms of fluctuations in the catechol concentration \[[@b84-sensors-05-00317]\]. Under most circumstances (some exceptions being stroke \[[@b98-sensors-05-00317]\] and death \[[@b99-sensors-05-00317],[@b100-sensors-05-00317]\]) these latter changes are mainly due to DOPAC, because the level of DA in striatal ECF has been estimated by a range of techniques to be less than 50 nM \[[@b101-sensors-05-00317]-[@b103-sensors-05-00317]\]. The main component of peak 2 is uric acid with a minor contribution from the 5HT metabolite, 5HIAA, when ∼300 μm CPEs are used \[[@b88-sensors-05-00317]\], whereas peak 2 recorded with 160 μm CPEs is due almost exclusively to 5HIAA \[[@b87-sensors-05-00317]\]. Changes in the height of peak 3 are directly proportional to changes in the extracellular concentration of methylated metabolites of DA. Normally this is HVA \[[@b59-sensors-05-00317]\] at an estimated baseline level of 10 μM \[[@b92-sensors-05-00317]\], but when monoamine oxidase is pharmacologically inhibited, 3MT may also contribute \[[@b97-sensors-05-00317]\].

The main advantage of CPEs is their stability over several months of recording *in vivo* \[[@b24-sensors-05-00317]\]. The evidence suggests that lipids present in the tissue remove pasting oil from the surface \[[@b35-sensors-05-00317]\], making it more powder-like \[[@b104-sensors-05-00317]\] and reversing the poisoning caused by proteins \[[@b47-sensors-05-00317]\]; see [Figure 5](#f5-sensors-05-00317){ref-type="fig"}. An early study by Adams *et al.* \[[@b104-sensors-05-00317]\] showed that certain carbon powders behave electrochemically like Pt, and that incremental addition of pasting materials reduced electron transfer rate constants (*k*^o^) for a variety of analytes. Furthermore, electrochemical pretreatment of the CPEs removed surface oil and tended to restore *k*^o^ to the 'dry' limit. The increase in *k*^o^ induced by lipid treatment has been observed for both Nujol \[[@b42-sensors-05-00317],[@b105-sensors-05-00317],[@b106-sensors-05-00317]\] and silicone oil \[[@b41-sensors-05-00317],[@b47-sensors-05-00317],[@b107-sensors-05-00317]\] based CPEs, although the time course of the effect is slower for the Nujol CPE presumably because of the higher oil content in the standard Nujol formulation for implantable CPEs. It appears that it is the continual process of oil removal by lipids and other surfactant media \[[@b41-sensors-05-00317],[@b42-sensors-05-00317],[@b47-sensors-05-00317],[@b108-sensors-05-00317],[@b109-sensors-05-00317]\] that enables CPEs to function efficiently in the present of proteins \[[@b47-sensors-05-00317]\]; see [Figure 5](#f5-sensors-05-00317){ref-type="fig"}. However, this factor may undermine the use of CPEs that have been bulk modified with lipophiles, such as stearic acid, for the detection of DA \[[@b110-sensors-05-00317],[@b111-sensors-05-00317]\] because such species can be removed from the electrode surface following contact with brain tissue \[[@b42-sensors-05-00317]\], although this point is still subject to debate \[[@b33-sensors-05-00317]\].

The principal disadvantage of CPEs is their comparatively large size, and neurochemical studies have been limited to relatively large brain areas such as dorsal striatum \[[@b112-sensors-05-00317]-[@b114-sensors-05-00317]\], nucleus accumbens \[[@b114-sensors-05-00317]-[@b116-sensors-05-00317]\], cortical regions \[[@b117-sensors-05-00317],[@b118-sensors-05-00317]\], pallidum \[[@b119-sensors-05-00317]\] and hippocampus \[[@b114-sensors-05-00317],[@b118-sensors-05-00317],[@b120-sensors-05-00317]\]. Other neurochemical analytes monitored by means of oxidation at implanted CPEs include: ascorbic acid \[[@b54-sensors-05-00317],[@b82-sensors-05-00317],[@b95-sensors-05-00317],[@b114-sensors-05-00317],[@b118-sensors-05-00317],[@b121-sensors-05-00317]-[@b127-sensors-05-00317]\], that may be linked to excitatory amino acid neurotransmission \[[@b120-sensors-05-00317],[@b128-sensors-05-00317]-[@b134-sensors-05-00317]\]; uric acid \[[@b87-sensors-05-00317]-[@b89-sensors-05-00317],[@b93-sensors-05-00317],[@b94-sensors-05-00317],[@b97-sensors-05-00317],[@b118-sensors-05-00317],[@b125-sensors-05-00317],[@b135-sensors-05-00317]-[@b137-sensors-05-00317]\], the concentration of which appears to reflect the extent of tissue reaction to the implanted electrodes \[[@b86-sensors-05-00317]-[@b89-sensors-05-00317]\] (see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}); 5-hydroxyindoleacetic acid (5HIAA) the monoamine oxidase metabolite of the neuromodulator 5HT, using the smaller implantable CPEs (125-μm diameter; see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) \[[@b87-sensors-05-00317]\]; and the reduction of molecular oxygen \[[@b121-sensors-05-00317],[@b123-sensors-05-00317],[@b138-sensors-05-00317]-[@b140-sensors-05-00317]\] that reflects local cerebral blood flow under certain conditions \[[@b138-sensors-05-00317]\].

The use of activated carbon fiber electrodes (***a***CFEs) as an alternative to CPEs for IVV studies has been driven mainly by their small diameter (usually \<10 μm) and their ability to resolve ascorbate and catechol peaks for periods of a few hours in brain tissue, using pulse \[[@b141-sensors-05-00317]-[@b143-sensors-05-00317]\] or staircase \[[@b144-sensors-05-00317]\] voltammetries. Clearly, the electro-oxidation of ascorbate and other species is more facile at ***a***CFEs \[[@b141-sensors-05-00317],[@b145-sensors-05-00317]\] than at unmodified CPEs \[[@b41-sensors-05-00317],[@b104-sensors-05-00317]\] in neutral buffer. However, exposure to lipid-rich media *in vitro*, or to brain tissue *in vivo*, has opposite effects on the two electrode types: lipid-treated CPEs are much more responsive to ascorbate ([Figure 5](#f5-sensors-05-00317){ref-type="fig"}) than lipid-treated ***a***CFEs \[[@b47-sensors-05-00317]\]. These results provide an explanation for the loss of ***a***CFE signal resolution after implantation *in vivo*, and also elucidate the mechanism whereby CPEs can be used over months in brain tissue ([Figure 4](#f4-sensors-05-00317){ref-type="fig"}), allowing long-term studies not possible with ***a***CFEs. The problem of loss of signal resolution after implantation of ***a***CFEs *in vivo* has been addressed by the use of removable electrode systems that allow easy electrode replacement in the same animal \[[@b146-sensors-05-00317]-[@b148-sensors-05-00317]\], although it has been suggested that no more than three insertions should be carried out on account of tissue disruption \[[@b149-sensors-05-00317]\].

A range of studies on the time-course of DA dynamics monitored in the ECF during behavior has been reported recently, using CFEs with either high-speed chronoamperometry \[[@b148-sensors-05-00317],[@b150-sensors-05-00317]\] or fast cyclic voltammetry \[[@b13-sensors-05-00317],[@b16-sensors-05-00317],[@b147-sensors-05-00317]\]. However, the ability to monitor brain DA metabolism continuously over periods of months in discrete brain areas is presently unique to CPEs, although the temporal resolution of the metabolite signal must be measured in minutes rather than seconds. Thus, the choice of technique for studying DA function will depend on the aims of the study. Here, for example, the stable HVA signal available with CPEs has been used to study long-term changes of DA turnover in response to drugs and behavioral manipulation.

Pharmacological Studies
=======================

The height of peak 3 (h~3~) recorded with chronically implanted CPEs (see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) has been used to study the effects of drugs on DA metabolism in different brain areas with a significant dopaminergic innervation \[[@b59-sensors-05-00317],[@b82-sensors-05-00317],[@b92-sensors-05-00317],[@b97-sensors-05-00317],[@b151-sensors-05-00317]-[@b153-sensors-05-00317]\]. Intraperitoneal (i.p.) administration of a DA synthesis inhibitor, α-methyl-*p*-tyrosine (AMPT, 250 mg/kg), caused a massive decrease in h~3~ associated with the loss of HVA from the ECF (see [Figure 1](#f1-sensors-05-00317){ref-type="fig"}) in frontal cortex, dorsal striatum and nucleus accumbens (94-98%); indeed, this effect is part of the evidence used to establish the link between peak 3 and DA pathways \[[@b59-sensors-05-00317],[@b117-sensors-05-00317]\]. Systemic administration of the DA receptor antagonist, haloperidol, that binds to most sub-types of DA receptors, led to substantial and sustained increase in ECF HVA in striatum and accumbens due to the blocking of the receptor-mediated negative feedback control of DA synthesis and release by this drug through both pre- and post-synaptic pathways. Despite the long-lasting effect of this dose of haloperidol (0.5 mg/kg i.p., ∼12 h), the CPEs were stable enough to monitor the return of HVA levels to baseline values (see [Figure 6](#f6-sensors-05-00317){ref-type="fig"}).

A summary of the effects of haloperidol and the non-specific DA receptor agonist, apomorphine, that [activates]{.ul} the same negative feedback loops, on the HVA signal in the three brain areas is given in [Figure 7](#f7-sensors-05-00317){ref-type="fig"}. These, and other, data have been used to suggest that the strength of negative feedback is weaker in the frontal cortex compared with the two sub-cortical regions \[[@b117-sensors-05-00317],[@b154-sensors-05-00317]\], and that this feedback regulation is also somewhat weaker in the accumbens (ventral striatum) compared with the dorsal striatum \[[@b117-sensors-05-00317]\].

More sophisticated studies on the long-term effects of receptor ligands on the HVA signals, recorded using CPEs in striatum and accumbens, have been carried out by Brose *et al.* \[[@b152-sensors-05-00317],[@b153-sensors-05-00317]\]. In one investigation, that involved 11 days of continuous voltammetric recording \[[@b153-sensors-05-00317]\], an anxiogenic β-carboline (N-methyl-β-carboline-3-carboxylate) was found to have different effects in these two forebrain regions. There was an initial depression of HVA levels in the accumbens on the day of the injection that returned to baseline the following day, but then increased on days 3-6 after administration before returning again to baseline levels. No effect was observed for striatal HVA. These results have been used to highlight the role of mesolimbic DA in the behavioral and therapeutic effects of benzodiazepines \[[@b152-sensors-05-00317],[@b153-sensors-05-00317]\].

Behavioral Studies
==================

The release of DA in sub-cortical brain areas, specifically the dorsal striatum \[[@b155-sensors-05-00317]\] and nucleus accumbens \[[@b156-sensors-05-00317]\] has long been recognized as an important factor in the expression of motor behaviors \[[@b157-sensors-05-00317]\]. However, many of these early studies implicating neurotransmitters in specific behaviors involved major perturbations of the brain, such as lesioning identifiable pathways \[[@b12-sensors-05-00317],[@b158-sensors-05-00317]\], infusion of drugs into individual brain areas \[[@b155-sensors-05-00317],[@b159-sensors-05-00317]\], or post-mortem assays of brain tissue \[[@b160-sensors-05-00317],[@b161-sensors-05-00317]\]. The development of *in-vivo* monitoring techniques, such as IVV and cerebral microdialysis \[[@b15-sensors-05-00317],[@b38-sensors-05-00317],[@b162-sensors-05-00317]-[@b175-sensors-05-00317]\] now allows detection of the release and metabolism of endogenous neurotransmitters during behavior.

Different forms of IVV can be categorized on the basis of the time resolution achieved for detecting changes in the concentration of species in the ECF. Fast techniques with resolutions of the order of seconds or less are chronoamperometry, fast cyclic voltammetry, differential pulse amperometry and constant potential amperometry \[[@b29-sensors-05-00317],[@b36-sensors-05-00317],[@b37-sensors-05-00317],[@b39-sensors-05-00317],[@b176-sensors-05-00317],[@b177-sensors-05-00317]\], and these methods are generally used to detect stimulated changes in neurotransmitter overflow, although recent advances has allowed detection of non-stimulated DA release during behavior \[[@b147-sensors-05-00317]\]. Slow techniques with time resolutions of the order of several minutes are linear sweep, staircase, differential pulse and differential normal pulse voltammetries at slow scan rates. The latter are usually used in studies of neurotransmitter metabolites, as well as ascorbic and uric acids \[[@b29-sensors-05-00317],[@b36-sensors-05-00317],[@b89-sensors-05-00317],[@b132-sensors-05-00317]\]. The minimum interval between scans is limited not only by the sweep time but also by the time taken for the concentration of the electrolyzed species in the compartment around the implanted electrode tip to return to its unperturbed value by means of tortuous diffusion through the tissue matrix \[[@b46-sensors-05-00317]\]. Although the HVA signal recorded using staircase voltammetry (see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) falls into the slower category, the stability of the CPEs allows long-term behavioral studies not possible with either other voltammetric methods or microdialysis.

[Figure 8](#f8-sensors-05-00317){ref-type="fig"} shows an example of the parallel time-courses of DA metabolism in the striatum and simultaneously monitored motor activity levels over a 3-day period. Rats are nocturnal and show a significantly higher level of motor activity during the hours of darkness. Associated with this activity, striatal HVA levels are also increased. Moreover, the diurnal increase in HVA concentration in the ECF, expressed as the percentage change in h~3~ during the hours of darkness compared with baseline lights-on values, were significantly higher in striatum (52 ± 5%, n = 14) and accumbens (48 ± 7%, n = 14) compared with frontal cortex (20 ± 19%, n = 9) where the increase itself was not statistically significant \[[@b117-sensors-05-00317]\]. Correlation analyses have also been used to demonstrate the greater involvement of the nucleus accumbens in locomotion levels, whereas dorsal striatum may be more important in the expression of patterns of movement and posture \[[@b157-sensors-05-00317],[@b178-sensors-05-00317],[@b179-sensors-05-00317]\].

In another study, during which the HVA signal was recorded continuously over a 2-week period \[[@b180-sensors-05-00317]\], a very simple model of jet-lag was applied to the diurnal recordings illustrated in [Figure 8](#f8-sensors-05-00317){ref-type="fig"}. Reversal of the light-dark conditions on day 6 caused a breakdown in the correlations between diurnal motor activity levels and DA metabolism (HVA) that are normally observed in both dorsal and ventral striatum (see [Figure 8](#f8-sensors-05-00317){ref-type="fig"}). The correlation gradually became re-established over the following days, suggesting that DA neurotransmission, at least in the accumbens, might be involved in the development of symptoms associated with jet-lag. It is interesting to note that benzodiazepine receptor agonists are used to reduce sleep latency, increase total sleep time, and decrease awakenings in humans \[[@b181-sensors-05-00317]\], and have also been shown to affect HVA levels recorded with CPEs in accumbens, but not striatum, in animal models \[[@b153-sensors-05-00317]\].

Studies involving lever pressing for food reward have been used to explore the application of CPEs to investigate well defined experimental designs in psychology \[[@b92-sensors-05-00317],[@b135-sensors-05-00317]\]. Increases in dopaminergic activity, reflected in the HVA signal, were observed in both dorsal striatum \[[@b92-sensors-05-00317]\] and accumbens \[[@b135-sensors-05-00317]\] following bouts of trained lever pressing. Furthermore, in individual subjects, both the behavioral response rates and the corresponding increases in peak 3 (see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) remained stable when studied periodically over a 3-month period \[[@b135-sensors-05-00317]\]. These results represent another demonstration of the exceptional stability of CPEs implanted in the brain, and equally importantly, evidence that the initial surgery and the perturbations associated with chronic electrode implantation do not interfere unduly with relatively subtle behaviors recorded over periods of months.

Conclusions
===========

Extensive characterization of the response of CPEs *in vitro* and *in vivo* has shown that peak 3 recorded with either staircase or linear sweep voltammetry in brain regions receiving a significant dopaminergic innervation is due to the oxidation of methylated metabolites of DA, that is almost exclusively HVA. The stability of CPE over months of recording provides a useful approach to investigating the long-term effects of drugs on DA activity in specific brain regions, as well as behavioral studies not possible with other *in-vivo* monitoring techniques.
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![Schematic representation of a dopamine (DA) nerve terminal, including synthesis from tyrosine (Tyr) *via* tyrosine hydroxylase (TH) and DOPA decarboxylase (DD) and storage in vesicles (V). On arrival of an action potential (AP), the depolarization resulting from the influx of Na^+^ leads to opening of Ca^+2^ ion channels (ICs). The consequent influx of Ca^+2^ causes a variety of biochemical cascades, one of which induces fusion of V and release of the stored DA. Metabolic enzymes involved in regulating the concentration of DA include monoamine oxidase (MAO) in the terminal and post-synaptic catechol-O-methyltransferase (COMT), producing mainly DOPAC and homovanillic acid (HVA). DA action is mediated by both pre- and post-synaptic receptors (R) that are linked to ICs or "second messenger" enzymes (ENZ-SM), such as adenylate cyclase. Levels of synaptic DA are also controlled by specific uptake channels (U), through which DA can also leak from the cytoplasm. Color code: grey (ionic events); red (enzyme-mediated processes); magenta (neurotransmitter, DA); blue (DA metabolites). See [Figure 2](#f2-sensors-05-00317){ref-type="fig"} for further details of the biochemical pathways.](sensors-05-00317f1){#f1-sensors-05-00317}

![Schematic representation of some of the biochemical pathways involved in the synthesis and metabolism of dopamine (DA). Precursor tyrosine is converted in the rate-determining synthesis step by tyrosine hydroxylase (TH) into L-DOPA whose cytoplasmic concentration is kept low by rapid conversion to DA by DOPA decarboxylase (DD). DA can be degraded into neuro-inactive forms by a number of pathways. The most important of these involve monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) whose main products are 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). 3-Methoxytyramine (3-MT) is unusual among metabolites in that it has a higher affinity for the DA uptake carrier than DA itself \[[@b52-sensors-05-00317]\] and therefore levels of 3MT in the ECF are very low \[[@b53-sensors-05-00317]\]. See [Figure 1](#f1-sensors-05-00317){ref-type="fig"} for anatomical context.](sensors-05-00317f2){#f2-sensors-05-00317}

![Schematic representation of an implantable CPE constructed from Teflon-coated wire. After soldering a gold clip to facilitate later connection to the potentiostat, a small cavity (∼0.5 mm long) is made by drawing the insulation over the metal wire (usually Ag or Pt-Ir). The carbon paste should be packed carefully into a cavity using a sleeved plunger of the same wire. If the paste is too loose or the cavity too short, the extracellular fluid may penetrate to the metal producing large background currents after a few days. If packed too tightly, the Teflon may crack, again allowing electrolyte into the cavity.](sensors-05-00317f3){#f3-sensors-05-00317}

![Samples of background-subtracted staircase voltammograms, expressed as current density, recorded at 5 mV/s with either 10T (320-μm diameter) or 5T (160-μm diameter) CPEs (see [Figure 3](#f3-sensors-05-00317){ref-type="fig"}) chronically implanted in rat striatum for periods of up to 6 months. The main difference between the responses obtained with these two dimensions of CPE is the size and nature of peak 2. Both the absolute current density peak-2 height, and the relative contributions of 5HIAA and uric acid to this peak, are different because of differences in the extent of tissue reaction to the implanted electrodes \[[@b86-sensors-05-00317]-[@b89-sensors-05-00317]\].](sensors-05-00317f4){#f4-sensors-05-00317}

![Differential staircase voltammograms recorded sequentially *in vitro* for 1 mM ascorbate with a CPE in phosphate buffer (PBS, pH 7.4) containing various treatment media: (a) background electrolyte, PBS; (b) 10% protein, bovine serum albumin (BSA), in PBS; and then (c) 10% lipid, phosphatidylethanolamine (PEA), in PBS. The current scales are the same to compare the effects of treatment on electrode sensitivity. Although the start potential differs because of different peak potential values, the voltage range is the same in all three cases (600 mV) so that peak width can be compared visually. Compare (c) with peak 1 in [Figure 4](#f4-sensors-05-00317){ref-type="fig"}. See Ref. \[[@b47-sensors-05-00317]\] for more detailed data and discussion.](sensors-05-00317f5){#f5-sensors-05-00317}

![Time-course over 24 h of the effect of haloperidol (0.5 mg/kg i.p.) on the HVA signal (height of peak 3; see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) recorded at 12-min intervals in the dorsal striatum \[[@b59-sensors-05-00317]\].](sensors-05-00317f6){#f6-sensors-05-00317}

![Mean ± SEM for the maximum effects of haloperidol (0.5 mg/kg i.p.) and apomorphine (2 mg/kg i.p.) on the height of peak 3 (see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) recorded in three brain regions, expressed as a percentage of the pre-injection value (see [Figure 6](#f6-sensors-05-00317){ref-type="fig"} for sample time-course). The effect of haloperidol was similar in dorsal striatum (ST, n = 9) and nucleus accumbens (NAcc, n = 6), but significantly smaller in frontal cortex (FCx, n = 6, \*P \< 0.05) compared with both ST and NAcc. The effect of apomorphine was also similar in ST (n = 7) and NAcc (n = 6), but significantly smaller in FCx (n = 4, \*P \< 0.05) compared with both sub-cortical areas \[[@b117-sensors-05-00317]\].](sensors-05-00317f7){#f7-sensors-05-00317}

![Time course over 3 days of changes in the HVA signal (peak 3, see [Figure 4](#f4-sensors-05-00317){ref-type="fig"}) recorded with a CPE in the striatum of a freely-moving rat at 12-min intervals (blue) and simultaneously monitored motor activity (red). Each day\'s recording started at 12.00 h, with lights off from 20.00 h to 08.00 h as indicated by the light/dark band (center). The period shown corresponds to days 3 to 6 of a longer recording period, and is a demonstration of the stability of CPEs in brain tissue. These results reveal the tight correlation that normally exists between the diurnal pattern of spontaneous locomotion observed behaviorally and the activity of DA terminals in the striatum (both dorsal and ventral) \[[@b117-sensors-05-00317]\].](sensors-05-00317f8){#f8-sensors-05-00317}
